Inhibikase Therapeutics Inc: Will Submit Ind Application to FDA for Ikt-001Pro as Treatment for Pulmonary Arterial Hypertension Early in Q3
inhibikase therapeutics將在第三季度初向FDA提交Ikt-001Pro治療肺動脈高壓的IND申請。
Inhibikase Therapeutics Inc: Will Submit Ind Application to FDA for Ikt-001Pro as Treatment for Pulmonary Arterial Hypertension Early in Q3
inhibikase therapeutics將在第三季度初向FDA提交Ikt-001Pro治療肺動脈高壓的IND申請。
譯文內容由第三人軟體翻譯。